182 related articles for article (PubMed ID: 12703198)
21. Oncology drug discovery and clinical trial testing: who's listening?
Seitz DE
Cancer Invest; 1992; 10(4):327-9. PubMed ID: 1628229
[No Abstract] [Full Text] [Related]
22. Moderate antiproliferative effect of the antifolate CB3717 in the BN myeloid leukaemia model.
Ermens AA; Lindemans J; Abels J
Br J Cancer; 1988 Apr; 57(4):405-7. PubMed ID: 3164630
[No Abstract] [Full Text] [Related]
23. [Factors of the therapeutic effectiveness of 5-fluorouracil].
Manziuk LV; Donenko FV; Sitdikova SM; Moroz LV
Vopr Onkol; 1996; 42(2):31-6. PubMed ID: 8815630
[No Abstract] [Full Text] [Related]
24. Pharmacogenetics of folate-related drug targets in cancer treatment.
Robien K; Boynton A; Ulrich CM
Pharmacogenomics; 2005 Oct; 6(7):673-89. PubMed ID: 16207145
[TBL] [Abstract][Full Text] [Related]
25. Thymidylate synthase as a target in cancer chemotherapy.
Peters GJ; van der Wilt CL
Biochem Soc Trans; 1995 Nov; 23(4):884-8. PubMed ID: 8654859
[No Abstract] [Full Text] [Related]
26. Antifolate inhibitors of thymidylate synthase as anticancer drugs.
Jarmuła A
Mini Rev Med Chem; 2010 Nov; 10(13):1211-22. PubMed ID: 20854257
[TBL] [Abstract][Full Text] [Related]
27. The biochemist's outlook on cancer research.
Friedkin M
Fed Proc; 1973 Dec; 32(12):2148-53. PubMed ID: 4585035
[No Abstract] [Full Text] [Related]
28. Novel therapeutic developments other than EGFR and VEGF inhibition in colorectal cancer.
Wilson RH
Oncologist; 2006 Oct; 11(9):1018-24. PubMed ID: 17030644
[TBL] [Abstract][Full Text] [Related]
29. Clinical application of the concept of methotrexate plus 5-FU sequence-dependent "synergy": how good is the evidence?
Browman GP
Cancer Treat Rep; 1984 Mar; 68(3):465-9. PubMed ID: 6200218
[No Abstract] [Full Text] [Related]
30. New targets for cancer chemotherapy.
Arbuck SG; Dancey J; Pluda JM; Grochow L; Murgo AJ; Ivy P; Wright J; Blaylock B; Via LE; Sausville EA
Cancer Chemother Biol Response Modif; 2001; 19():237-88. PubMed ID: 11686017
[No Abstract] [Full Text] [Related]
31. Topoisomerase II inhibitors.
Clapp JM; Hande KR
Cancer Chemother Biol Response Modif; 2002; 20():125-49. PubMed ID: 12703203
[No Abstract] [Full Text] [Related]
32. New anticancer agents in clinical development.
Eckardt J; Eckhardt G; Villalona-Calero M; Drengler R; Von Hoff D
Oncology (Williston Park); 1995 Dec; 9(12):1321-8; 1331; discussion 1332-4. PubMed ID: 8771106
[TBL] [Abstract][Full Text] [Related]
33. Searching for the Achilles' heel of melanoma cells: new treatment modalities.
Melnikova VO; Bar-Eli M
Pigment Cell Melanoma Res; 2008 Oct; 21(5):505-6. PubMed ID: 18713130
[No Abstract] [Full Text] [Related]
34. In vitro effects of Plasmodium falciparum dihydrofolate reductase inhibitors on normal and cancer cell proliferation.
Rossi T; Coppi A; Bruni E; Sgobba M; Degliesposti G; Rastelli G
ChemMedChem; 2008 Mar; 3(3):421-4. PubMed ID: 17973282
[No Abstract] [Full Text] [Related]
35. Histone deacetylase inhibitors in cancer therapy.
Fouladi M
Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962
[No Abstract] [Full Text] [Related]
36. Novel 2-amino-4-oxo-5-arylthio-substituted-pyrrolo[2,3-d]pyrimidines as nonclassical antifolate inhibitors of thymidylate synthase.
Gangjee A; Jain HD; Kisliuk RL
Bioorg Med Chem Lett; 2005 May; 15(9):2225-30. PubMed ID: 15837298
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors.
Beutel G; Glen H; Schöffski P; Chick J; Gill S; Cassidy J; Twelves C
Clin Cancer Res; 2005 Aug; 11(15):5487-95. PubMed ID: 16061865
[TBL] [Abstract][Full Text] [Related]
38. Determinants of the therapeutic efficacy of thymidylate synthase inhibitors.
Peters GJ; Kuiper CM; van Triest B; Backus H; van der Wilt CL; van Laar JA; Jansen G; van Groeningen CJ; Pinedo HM
Adv Exp Med Biol; 1998; 431():699-704. PubMed ID: 9598155
[No Abstract] [Full Text] [Related]
39. Benzoyl ring halogenated classical 2-amino-6-methyl-3,4-dihydro-4-oxo-5-substituted thiobenzoyl-7H-pyrrolo[2,3-d]pyrimidine antifolates as inhibitors of thymidylate synthase and as antitumor agents.
Gangjee A; Jain HD; McGuire JJ; Kisliuk RL
J Med Chem; 2004 Dec; 47(27):6730-9. PubMed ID: 15615522
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics, safety, and efficacy of a liposome encapsulated thymidylate synthase inhibitor, OSI-7904L [(S)-2-[5-[(1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]amino-1-oxo-2-isoindolynl]-glutaric acid] in mice.
Desjardins J; Emerson DL; Colagiovanni DB; Abbott E; Brown EN; Drolet DW
J Pharmacol Exp Ther; 2004 Jun; 309(3):894-902. PubMed ID: 14982966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
